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Purpose: To report ciliary body seeding 20 years after pars plana transvitreal fine needle
aspiration biopsy (FNAB) of choroidal melanoma.
Case Report: 67-year-old man with choroidal melanoma in left eye was previously
managed with pars plana FNAB using a 25-gauge needle followed by plaque
radiotherapy. Twenty years later, choroidal melanoma was regressed but there was a
small flat focus of scleral pigment 3.0mm from the limbus at the FNAB site. Ultrasound
biomicroscopy showed a contiguous ciliary body mass measuring 3.1mm in thickness.
Tumor seeding in the anterior chamber angle was noted inferiorly. These findings
suggested melanoma recurrence along the needle tract. Treatment was performed
with Iodine-125 radioactive plaque covering entire anterior segment and ciliary body
recurrence. The tumor regressed to 2.2mm over one year.
Conclusion: Pars plana transvitreal FNAB of choroidal melanoma resulted in needle tract
seeding in ciliary body and episcleral region 20 years later.
Keywords: Choroid; Ciliary Body; Extraocular Extension; Fine-Needle Aspiration Biopsy;
Melanoma; Seeding
J Ophthalmic Vis Res 2020; 15 (2): 252–255
INTRODUCTION
The diagnosis of uveal melanoma is usually based
on ophthalmoscopic appearance and results
of noninvasive tests, such as ultrasonography,
transillumination, fluorescein angiography, and
optical coherence tomography.[1, 2] Fine-needle
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aspiration biopsy (FNAB) is occasionally performed
to obtain a cytopathologic confirmatory diagnosis
of suspected but atypical uveal melanoma.[1–3]
Moreover, over the past two decades, FNAB has
been used extensively for prognostication of uveal
melanoma based on the results of cytogenetic
testing and gene expression profiling. Genetic test-
ing has markedly increased the number of FNABs
being performed in eyes with uveal melanoma.[1–3]
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FNAB for choroidal melanoma, depending on
the tumor location, can be performed safely with
the direct transscleral approach into the tumor base
or pars plana transvitreal approach into the tumor
apex.[1–3] Transient localized subretinal/preretinal
or intravitreal hemorrhage at the tumor biopsy
site is the most common complication of this
procedure.[1–3] Seeding along the needle tract is a
rare complication.[4–7]
Here, we report a case of melanoma seed-
ing along the needle tract in the ciliary body
and extraocular tissue at the pars plana needle
entrance site 20 years after pars plana transvitreal
FNAB of choroidal melanoma.
CASE REPORT
A 67-year-old Caucasian man was referred to
the Oncology Service, Wills Eye Hospital, for an
evaluation of a peripheral iris elevation at the 9:00
o’clock position in the left eye (OS). He had a history
of choroidal melanoma OS, confirmed using FNAB
and treated with iodine-125 plaque brachytherapy
20 years before referral. In the FNAB, a 25-guage
needle bent to an 85° angle was inserted via a 1.5-
mm partial-thickness scleral incision approximately
3.5 mm posterior to the limbus OS along the 10:00
o’clock meridian. Under indirect ophthalmoscopy,
the needle was advanced through the vitreous
cavity into the choroidal mass, and aspiration was
performed. After aspiration, mild vitreous hemor-
rhage was noted, and hemostasis was achieved
by applying direct pressure on the globe. A nylon
suture was used to close the scleral incision site.
Cytological examination of the aspirate showed
mixed spindle and epithelioid melanoma cells.
On examination at our center, 20 years later,
visual acuity was 20/20 in the right eye (OD) and
20/25 OS. Intraocular pressure was 9 mmHg OD
and 11 mmHg OS. The right eye was unremarkable.
The OS had a superonasal dilated episcleral
blood vessel that perforated the sclera 3 mm from
the limbus [Figure 1(A)]. A flat, darkly pigmented
episcleral mass, measuring 0.2 mm in the basal
diameter was noted at the 10:00 o’clock meridian
at the site of entry of the episcleral vessel [Figure
1(A)]. The iris was elevated nasally along the 9:00
o’clock meridian. Gonioscopy revealed confluent
seeding in the inferior angle and multiple tiny
seeds over the temporal and superior trabecular
meshwork. Funduscopy of the left eye revealed
a flat retina with regressed choroidal melanoma
measuring 8.0 × 6.0mm in basal dimensions and
1.9mm in thickness. The tumor was surrounded by
an area of retinal pigment epithelium atrophy, and
nasal retinal vessels had occlusion [Figure 1(B)].
Transillumination of the ciliary body revealed a
superonasal dark shadow in the pars plana [Figure
1(C)]. Ultrasound biomicroscopy demonstrated a
ciliary body mass of 3.1mm thickness at the site
of the shadow, causing forward bulging of the
peripheral iris [Figure 1(D)]. Based on these find-
ings, a clinical diagnosis of ciliary body melanoma
with anterior chamber invasion, angle seeding, and
early extraocular extension was made.
The patient was treated with a round 18mm
custom-designed 125I radioactive plaque covering
the entire anterior segment and delivering a dose
of 7,000 cGy to the tumor apex at a depth of 4.0
mm. FNAB of the ciliary body tumor for cytogenetic
evaluation at the time of plaque placement showed
a loss of 1p, disomy 3, gain of 6p, and disomy 8.
At the one-year follow-up, choroidal melanoma had
remained regressed at 1.9mm thickness, and ciliary
body melanoma had regressed to 2.2mm thick-
ness. The small extrascleral component remained
stable with no evidence of orbital recurrence on
clinical examination or orbital imaging. Systemic
evaluation showed no evidence of systemic metas-
tasis.
DISCUSSION
FNAB was initially used to obtain tissue for
cytopathologic diagnosis of atypical tumors in the
management of choroidal melanoma. Recently, its
use has expanded to cytogenetic prognostication
of the metastatic risk.[1–3] Therefore, the use of
FNAB for choroidal melanoma has increased at
many centers. A recent study on reactions to
and desire for prognostic testing for choroidal
melanoma showed that even in the absence
of prophylactic therapies to improve prognosis,
97% of respondents preferred knowing prognostic
information.[8]
A serious potential complication of FNAB is
extraocular tumor extension. Nonetheless, sev-
eral studies proved the safety of FNAB for
choroidal melanoma with the transscleral or pars
plana transvitreal approach,[1–3] and cases of
extraocular extension are rare.[4–7] Schefler et al[4]
reported extraocular extension in four patients
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Figure 1. (A) Dilated episcleral blood vessel superonasally perforates the sclera 3mm from the limbus with a pigmented spot of
extrascleral extension (arrow). Additional invasion of the peripheral iris is noted nasally. (B) Fundus photograph of the same eye
shows irradiated choroidal melanoma with surrounding retinal pigment epithelium atrophy. (C) Transillumination demonstrates
a dark shadow in the pars plana region (arrow). (D) Ultrasound biomicroscopy shows a ciliary body mass measuring 3.1mm in
thickness with bowing forward of the peripheral iris.
with uveal melanoma, but three of them had
undergone vitrectomy and/or open biopsy in addi-
tion to FNAB. The interval between FNAB and
the detection of extraocular extension in their
series ranged from five months to approximately
nine years. Caminal et al[5] reported epibulbar
tumor seeding eight months after pars plana
transvitreal FNAB in one patient using a 25-
gauge needle and infusion. Mashayekhi et al[6]
reported one patient with extraocular exten-
sion of ciliochoroidal melanoma one and a half
years after transscleral FNAB using a 25-gauge-
needle without infusion. Koch et al[7] reported
pars plana seeding with localized extraocular
extension 3.5 years after transretinal biopsy of
choroidal melanoma using a 25-gauge vitrectomy
probe followed by Ruthenium-106 plaque radio-
therapy.
Laboratory quantification of tumor seeding fol-
lowing FNAB of the enucleated globes with uveal
melanoma showed significantly fewer tumor cells
in the needle tract of the pars plana transvitreal or
translimbal approach compared to the transscleral
approach.[9] Other factors possibly associated with
a higher risk of tumor seeding via the needle
tract include a larger needle gauge, higher num-
ber of needles passing into the tumor, vitreous
leakage through the scleral entrance site, manip-
ulation of the needle within the tumor, and a
higher number of viable malignant cells aspirated.
Additionally, fluid infusion into the vitreous cavity
could theoretically increase the risk for tumor
cell egress. Immediate application of cryotherapy
at the scleral entrance site as the needle is
removed and application of radioactive plaque
over the scleral entrance site could prevent tumor
seeding.[4]
The long interval of 20 years between FNAB and
the detection of ciliary body seeding in our case is
an indication of the low-grade nature of the treated
choroidal melanoma. In addition, the location of
seeding in the ciliary body, a region hidden from
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direct view, contributed to the delay in detection of
seeding. Bosello et al reported delayed recurrence
of uveal melanoma 45 years after treatment, pos-
sibly caused by the low malignant potential, tumor
dormancy, and host immunity.[10]
Due to the lack of histopathology and molecular
evidence, we cannot conclude that the ciliary body
seed in our patient was similar to the original
choroidal tumor. Nevertheless, the possibility of a
new ciliary bodymelanoma developing in the same
eye as the choroidalmelanoma exactly at the site of
sclerotomy performed for FNAB is low, supporting
our belief that the tumor in the ciliary body was a
seed from the original choroidal tumor.
In summary, we report a rare case of FNAB-
related needle tract seeding into the ciliary body
with anterior chamber invasion and extraocular
extension detected 20 years after pars plana
transvitreal FNAB of choroidal melanoma that was
performed with a 25-gauge needle. Long-term
monitoring of all eyes with treated uveal melanoma
is recommended, particularly at the scleral site of
needle biopsy.
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